DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

All news

Neutral impactCompany

Epigral Limited — Spurt in Volume

NSE 1 hr ago·22 Jul 2026, 5:24 am

Epigral

Epigral Limited has seen a notable rise in trading volume on the stock exchange. In response to this unusual activity, the exchange has written to the company to request an explanation. Epigral has now submitted its official reply to the market.

This development is significant for investors as it signals heightened market interest in the company. While the exchange is seeking clarity to safeguard investor interests, the spike in volume suggests that the market is reacting to new information or expectations about the firm's future performance.

Investors should monitor the company's official disclosures for further details. Understanding the specific reasons behind the volume surge will be key to assessing its potential impact on the stock price moving forward.